On the Effects of Anticholinergic Agents on Muscarinic Receptors of Different Localization

  • D. A. Kharkevich
  • A. P. Skoldinov
  • D. N. Samoilov
  • V. A. Shorr
Part of the Advances in Behavioral Biology book series (ABBI, volume 25)


Dissimilarities in the sensitivity of muscarinic receptors of different organs to agents of various pharmacological groups has been noted (4-6, 8-11, 14, 16-18). Thus, the search for compounds which block muscarinic receptors of definite localization (heart, exocrine glands, smooth muscles of visceral organs) is warranted and will stimulate the synthesis of antimuscarinic agents of cardiotropic or broncholytic action and possibly of selective blockers of glandular secretory activity, etc. In addition, particular morphological and functional properties of muscarinic receptors of various effector cells could be characterized with the use of such selective drugs.


Muscarinic Receptor Anticholinergic Agent Atropine Sulfate Anticholinesterase Activity Quaternary Nitrogen Atom 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Aronstam, R.S., Abood, L.G. and Baumgold, J. (1977): Biochem. Pharmacol. 26: 1689–1695.CrossRefGoogle Scholar
  2. 2.
    Barlow, R.B., Bremner, J.B. and Soh, K.S. (1978): Brit. J. Pharmacol. 62: 39–50.CrossRefGoogle Scholar
  3. 3.
    Benfey, B.G., Yong, M.S., Belleau, B. and Melchiorre, C. (1979) Canad. J. Physiol. Pharmacol. 57:41–47.CrossRefGoogle Scholar
  4. 4.
    Kharkevich, D.A. (1957): Farmakol. i Toksikol. 6:46–51.Google Scholar
  5. 5.
    Kharkevich, D.A. (1963):Abst. Sec. Int. Pharmacol. Meeting, Prague, 166, No.588.Google Scholar
  6. 6.
    Kharkevich, D.A. (1965): Farmakol. i Toksikol. 3:305–309. (Fed. Proc. 25,T521, 1966).Google Scholar
  7. 7.
    Kharkevich, D.A. (1966): Farmakol. i Toksikol. 1:47–53.Google Scholar
  8. 8.
    Kharkevich, D.A. (1970): Farmakol. i Toksikol. 4:395–399.Google Scholar
  9. 9.
    Kharkevich, D.A. (1970): Farmakol. i Toksikol. 5:531–536.Google Scholar
  10. 10.
    Kharkevich, D.A. (1974): Farmakol. i Toksikol. (Kiev, vyp) 9:94–102.Google Scholar
  11. 11.
    Kharkevich, D.A. (1974): J. Pharm. Pharmacol. 26:153–165.CrossRefGoogle Scholar
  12. 12.
    Kharkevich, D.A. (1975): Proc. Int. Congr. Pharmacol. 1: 33–47.Google Scholar
  13. 13.
    Kharkevich, D.A. and Skoldinov, A.P. (1976): J. Union Mendeleev’s Chem. Soc. 21:124–129.Google Scholar
  14. 14.
    Richer, W.F. Jr. and Wescoe, W.C. (1951): Ann. NY Acad. Sci. 54:373–394.CrossRefGoogle Scholar
  15. 15.
    Rosen, J.M., Rauckman, E.J. and About-Donia, M. B. (1976): Biochem. Pharmacol. 25:2761–2764.CrossRefGoogle Scholar
  16. 16.
    Samoilov, D.N. (1971): Farmakol. i Toksikol, 4:413–420.Google Scholar
  17. 17.
    Saxena, P.R. and Bonta, J.L. (1970): Eur. J. Pharmacol. 11: 332–341.CrossRefGoogle Scholar
  18. 18.
    Shorr, V.A. (1972): Farmakol. i Toksikol. 4:426–431.Google Scholar

Copyright information

© Plenum Press, New York 1981

Authors and Affiliations

  • D. A. Kharkevich
    • 1
  • A. P. Skoldinov
    • 1
  • D. N. Samoilov
    • 1
  • V. A. Shorr
    • 1
  1. 1.Department of PharmacologyFirst Medical Institute and Institute of Pharmacology, Academy of Medical SciencesMoscowUSSR

Personalised recommendations